ERLOTINIB

Erlotinib is an EGFR inhibitor preventing tumor cell proliferation, used in lung and pancreatic cancer. Side effects include rash, diarrhea, and fatigue.

SKU: 78d10dfa0a58 Category: Tag:

Product Description


Mechanism of Action

Erlotinib is a selective small‑molecule inhibitor of EGFR (ErbB1) tyrosine kinase. It binds the ATP‑binding site of EGFR, blocking autophosphorylation and downstream signalling across the RAS–RAF–MEK–ERK and PI3K–AKT pathways. It is particularly effective in EGFR‑activating mutation models.

Benefits and Advantages

Used in EGFR‑pathway research, kinase‑inhibition profiling, oncogene‑driven tumour modelling, and resistance‑mutation evolution assays.

Side Effects and Risks

Risks include rash, diarrhea, hepatotoxicity, interstitial lung disease (rare) and photosensitivity. Handle with EGFR‑inhibitor precautions.

Datasheet


Molecular Formula

C22H23N3O4

Molecular Weight

393.4 g/mol

CAS Number

183321-74-6

Storage Condition

Store at 25 °C (77 °F); excursions permitted to 15 – 30 °C (59 – 86 °F).

Solubility

Very slightly soluble (hydrochloride salt – maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)

Purity

Purity information is available upon request (COA).

Synonym

Erlotinib; 183321-74-6; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-; erlotinibum

IUPAC/Chemical Name

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

InChl Key

AAKJLRGGTJKAMG-UHFFFAOYSA-N

InChl Code

InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)

References

https://pubchem.ncbi.nlm.nih.gov/compound/176870;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download